Blog

Rare disease patient data is generated from a wide range of sources. We examine specialty pharmacy data and rare disease registries.

The very name “rare disease” implies that the average person should expect to meet someone with a rare disease infrequently, if ever. Each individual rare disease in fact affects only a small portion of the human population. Taken together, rare diseases as a whole affect millions of people worldwide. Those who have a rare disease

As work on genetics has advanced, so has the creation of biologics and biosimilars. Today, biosimilars are more common, changing the specialty drug landscape.

Tracking the right specialty pharma KPIs matters. Here’s what to consider and how to implement digital tracking tools.

Patient Services plays a key integrative role both before and after product launch, and along with Hub tools can better integrate patient care.

The FDA’s recent approval of Roctavian marks the first approved gene therapy for adults with severe hemophilia A.

Identifying the right key stakeholders early and including them in the planning offers a greater chance for pharma product launch success.

Patient-reported outcomes (PROs) are a valuable source of information. To unlock the data’s insights, manage it effectively.

Intermediaries in the distribution chain, pharmacy benefit managers (PBMs) play a key role in connecting patients to rare disease treatments.